Organogenesis Holdings Inc.

Organogenesis Holdings Inc. (ORGO) is a regenerative medicine company focused on advanced wound care and surgical biologics that reached the public markets through a SPAC transaction with Avista Healthcare Public Acquisition Corp., sponsored by Avista Capital Partners. The SPAC completed its initial public offering in 2016 and filed this Form 8-K with the SEC on October 30, 2018, during the period surrounding its business combination with Organogenesis. The merger ultimately closed in late 2018, with ORGO trading on Nasdaq under its current ticker. Visit SpacDesk and sign up for full data, filings, and deal analytics on ORGO and hundreds of other SPAC transactions.